DDrare: Database of Drug Development for Rare Diseases

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.9% physiological saline; ACZ885; ACZ885, 150mg/1.0ml; CANAKINUMAB; Canakinumab; Colchicine; Colchicine sprinkle capsules; Diagnostic Test: colchicine level measurement; IL-1 Trap; INN-Tocilizumab; Ilaris; Kineret; One additional blood sample during a planned blood test; Other: Colchicine Cessation; Other: Wheat flour; Probiotic; Rilonacept; RoActemra; RoActemra® 20mg/ml Konzentrat; TOCILIZUMAB; Tocilizumab; Tocilizumab Infusion RoAcemtra (EU); Wheat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004505-13-DE (EUCTR)	27/11/2017	21/08/2017	Tocilizumab for the Treatment of Familial Mediterranean Fever	Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever	Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: RoActemra ® 20mg/ml Konzentrat INN or Proposed INN: INN-Tocilizumab Other descriptive name: TOCILIZUMAB	University Hospital Tuebingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-004505-13-DE
(EUCTR)

27/11/2017

21/08/2017

Tocilizumab for the Treatment of Familial Mediterranean Fever

Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever

Adult patients with Familial Mediterranean Fever, who have active disease
MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: RoActemra ® 20mg/ml Konzentrat
INN or Proposed INN: INN-Tocilizumab
Other descriptive name: TOCILIZUMAB

University Hospital Tuebingen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Germany